. No in vitro or clinical trial data have shown whether the growth of germ cell tumours can be controlled by IFN. A phase II clinical trial was therefore conducted to determine the efficacy of lymphoblastoid IFN in patients with cytotoxic drug-resistant anaplastic (non-seminomatous) germ cell tumours as defined by Paradinas (1983) . Since it has been suggested that IFN may be more effective against slow growing rather than rapidly growing tumours (der Bosch & Zirvi, 1982) it was administered to a patient with unresectable differentiated teratoma. When a partial response was seen attempts were made to see if dose escalation enhanced the response and whether the tumour was also responsive to recombinant leukocyte A IFN.
Patients and methods
Lymphoblastoid IFN was given to 9 men and 1 woman who had residual tumour after receiving intensive cytotoxic chemotherapy for metastatic anaplastic germ cell tumours. All patients apart from patient No. 7 had initially responded to combination chemotherapy which included cisplatinum in all cases and etoposide in all but one. The residual tumour was considered active in 8 patients, because of rising AFP and/or HCG and enlarging tumour masses in 5 (patients 5, 7, 8, 9 and 10, see Table) , rising AFP alone in 2 (patients 1 and 4), and rising HCG in 1 (patient 6) (see below). Two Table I . It was started not less than 4 weeks after the last course of cytotoxic chemotherapy. Recombinant leukocyte A IFN (supplied by Roche Products Ltd., Welwyn Garden City, U.K.) was administered as described in the case history.
Results
There was progression of disease whilst on IFN as judged by enlargement of evaluable tumour masses and/or rising tumour markers in 8 of the 10 patients (patients 1 and 4-10) ( Table I ). In one of these patients (case history below, patient No. 6) a mixed response of his differentiated teratoma has been obtained for 24+ months. There was stabilization of evaluable masses in 2 patients (Nos. 2 and 3), who as previously discussed were later considered to have differentiated teratoma. Patient No. 2 had to stop IFN after only 3 weeks because of a digital vasculitis (Sangster et al., 1983) . Patient No. 1 developed a septicaemia which responded to antibiotics whilst on IFN. Toxicity was otherwise similar to that previously reported with IFN (Priestman, 1980; Scott et al., 1981) (Figure 2 ) and marginal shrinkage of the abdominal masses. He has administered the IFN himself and apart from the expected toxicity (rigors, fever, malaise) during the first two weeks of each course and when receiving the high dose infusions (fever, severe malaise and myelosuppression) experienced no side effects from either preparation of IFN.
Electron microscopy
Part of the left supraclavicular node mass and buffy coat from peripheral blood taken whilst patient No. 6 was receiving lymphoblastoid IFN were prepared for electron microscopy as previously described (Moss et al., 1982) . Tubuloreticular structures were found in peripheral blood lymphocytes and in endothelial cells within the differentiated teratoma mass (Figure 3 ). They were not seen in any other cells.
Discussion
This study suggests that lymphoblastoid IFN has no place in the treatment of cytotoxic drug-resistant anaplastic germ cell tumours. With only 8 patients with active anaplastic germ cell tumours in the sample there was a probability of 0.05 that a response rate of up to 35% was missed. In view of the toxicity of the IFN in these heavily pre-treated patients it was not considered ethical to continue the trial with the aim of obtaining a more statistically significant result. In the best centres, combination chemotherapy can induce a long term disease free state in over 80% of patients with anaplastic germ cell tumours Peckham et al., 1983; Vugrin & Golbey, 1983) . Therefore only patients who have become resistant to cytotoxic chemotherapy become eligible for trials of new agents.
This study reports the first demonstration of IFN inducing a response in differentiated (mature) teratoma. This is a complex tumour composed of somatic tissues derived from more than one germ cell layer and resembles mature tissue (Paradinas, 1983) . Elements of differentiated teratoma can be found mixed with malignant elements in the primary site of many patients with testicular germ cell tumours. After completing cytotoxic chemotherapy patients may have residual masses many of which on surgical removal are found to be composed of differentiated teratoma with no immature elements (McCartney et al., 1984; Peckham et al., 1983) . It is unclear whether this is due to selective killing by the chemotherapy of immature elements or induction of differentiation. Differentiated teratoma should be surgically resected where possible because it can invade locally and there is the potential for dedifferentiation into more malignant tissue (Loehrer et al., 1983) . This was manifested in patient No. 6 by a rising HCG concentration.
A response to a second course of IFN has previously been reported in a patient with non Hodgkin's lymphoma (Louie et al., 1981 ) but a response to two different types of IFN has not been previously reported. It is known that lymphoblastoid IFN contains at least eight different alpha sub-types and one of these is very similar to the pure sub-type of the recombinant leukocyte A IFN (Alan, 1982) . To determine whether response is sub-type specific would require the administration of another purified sub-type.
No randomised studies have shown whether the response rates to IFN are dose-dependent. However there is a suggestion from non randomized studies that higher response rates are seen with larger doses of IFN than lower doses but at the expense of greater toxicity. The mediastinal mass measurement of J.B. indicated a marginal additional response on dose escalation of lymphoblastoid IFN and the effect of larger doses was even more pronounced on the supraclavicular mass. However infusions of 170 MU lymphoblastoid IFN daily for 5 days failed to make the abdominal masses resectable.
It is unclear whether the action of the IFN on the masses of differentiated teratoma were mediated through an anti proliferative effect or through an effect on one of the many cellular enzymes which have been reported to be modulated by IFN (Sreevalasan et al., 1981) . Tubuloreticular structures appear to be a footprint for high concentrations of IFN and are seen in patients with systemic lupus erythematosis and Kaposi's sarcoma (Rich et al., 1983) . As they were only seen in the endothelial cells but not in the cystic teratoma cells of the supraclavicular mass that responded to IFN they do not appear to be a marker of response. Despite the dramatic response of the supraclavicular mass to IFN seen in patient No. 6, differentiated teratoma was found in the resected tissue. This tissue had previously been shown to be cystic on ultrasound and it is possible that the decrease in the size of the mass was solely due to resolution of the cystic fluid. Nevertheless a reduction in the size of a mass of differentiated teratoma in response to interferon could make the difference in future patients between a tumour being completely resected or not.
